These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 31136782)

  • 1. Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints.
    Lequeux A; Noman MZ; Xiao M; Sauvage D; Van Moer K; Viry E; Bocci I; Hasmim M; Bosseler M; Berchem G; Janji B
    Cancer Lett; 2019 Aug; 458():13-20. PubMed ID: 31136782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YY1 regulates cancer cell immune resistance by modulating PD-L1 expression.
    Hays E; Bonavida B
    Drug Resist Updat; 2019 Mar; 43():10-28. PubMed ID: 31005030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
    Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
    J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
    Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
    MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises.
    Tong B; Wang M
    Future Oncol; 2018 Sep; 14(21):2179-2188. PubMed ID: 29667847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application.
    Hu G; Tu W; Yang L; Peng G; Yang L
    Cancer Lett; 2020 Mar; 473():148-155. PubMed ID: 31911080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
    Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
    J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.
    Shien K; Papadimitrakopoulou VA; Wistuba II
    Lung Cancer; 2016 Sep; 99():79-87. PubMed ID: 27565919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies.
    Datta M; Coussens LM; Nishikawa H; Hodi FS; Jain RK
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():165-174. PubMed ID: 31099649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy.
    Song Y; Li Z; Xue W; Zhang M
    Immunotherapy; 2019 Apr; 11(6):515-529. PubMed ID: 30860441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The application of nanotechnology in immune checkpoint blockade for cancer treatment.
    Deng H; Zhang Z
    J Control Release; 2018 Nov; 290():28-45. PubMed ID: 30287266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies.
    Devereaux KA; Charu V; Zhao S; Charville GW; Bangs CD; van de Rijn M; Cherry AM; Natkunam Y
    Hum Pathol; 2018 Dec; 82():39-45. PubMed ID: 30539796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors.
    Heinhuis KM; Ros W; Kok M; Steeghs N; Beijnen JH; Schellens JHM
    Ann Oncol; 2019 Feb; 30(2):219-235. PubMed ID: 30608567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
    Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
    J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment.
    Yi M; Jiao D; Qin S; Chu Q; Wu K; Li A
    Mol Cancer; 2019 Mar; 18(1):60. PubMed ID: 30925919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
    Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
    Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application.
    Tray N; Weber JS; Adams S
    Cancer Immunol Res; 2018 Oct; 6(10):1122-1128. PubMed ID: 30279188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of exosomal PD-L1 in tumor progression and immunotherapy.
    Xie F; Xu M; Lu J; Mao L; Wang S
    Mol Cancer; 2019 Oct; 18(1):146. PubMed ID: 31647023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.